Galecto Highlights Key Strategic Priorities and Anticipated 2026 Milestones

Core Insights - Galecto, Inc. is advancing its pipeline with a focus on mutant calreticulin (mutCALR) targeting monoclonal antibodies, specifically DMR-001 and DMR-002, with IND submissions expected in mid-2026 and the second half of 2026 respectively [1][11] - The company has recently expanded its management team, enhancing its capabilities in hematology and oncology drug development [2][5][6] Company Strategy and Milestones - 2026 is anticipated to be a pivotal year for Galecto, with the initiation of clinical development for its anti-mutCALR pipeline candidates [4] - DMR-001 is designed to address a wide range of CALR mutations in essential thrombocythemia (ET) and myelofibrosis (MF), demonstrating potent activity in preclinical models [4][7] - The company plans to submit an IND for DMR-001 by mid-2026, with first-in-human dosing expected to follow [1][7] Financial Position - Galecto raised $285 million in a PIPE financing in November, providing a financial runway into 2029 to support multiple data milestones, including Phase 1 clinical proof-of-concept data for DMR-001 anticipated in 2027 [5][8] Management Team Expansion - Sherwin Sattarzadeh has been appointed as Chief Operating Officer, bringing over 20 years of experience in drug development [6] - Becker Hewes has been appointed as Chief Medical Officer, with a strong background in hematology/oncology drug development [6] Pipeline Overview - In addition to DMR-001, DMR-002 is also in development, with an IND submission planned for the second half of 2026 [11] - GB3226, a dual inhibitor for acute myeloid leukemia (AML), is expected to have its IND submission in the first quarter of 2026 [11]